Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST

Fineline Cube Jul 9, 2026
Company Deals

Xenovector and Jilin University Launch Strategic Partnership to Advance Gene-Edited Pig Organ Transplantation from Breakthrough to Affordable Healthcare

Fineline Cube Jul 9, 2026
Company Deals

Zhejiang Hisun Pharmaceutical and Tigermed Forge Strategic Alliance to Create End-to-End Innovative Drug Development Pipeline

Fineline Cube Jul 9, 2026
Company Deals

Transcenta Returns Select Lilly Assets in Portfolio Restructuring, Retains Blosozumab Rights

Fineline Cube Jul 8, 2026
Company Deals Digital

Hanx Biopharmaceuticals Partners with HUST-CityU Macau Institute to Establish AI-Driven Drug Discovery Joint Laboratory

Fineline Cube Jul 8, 2026
Policy / Regulatory

China’s National Health Commission Unveils 2026 Essential Medicines List, Adding 116 New Drugs with Full Insurance Coverage

Fineline Cube Jul 9, 2026
Company Drug

Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients

Fineline Cube Jul 9, 2026
Company Drug

Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs

Fineline Cube Jul 9, 2026
Company Drug

Sino Biopharmaceutical’s LM-108 Gains CDE BTD for Gastric Adenocarcinoma

Fineline Cube Jun 27, 2025

Sino Biopharmaceutical Ltd (HKG: 1177) announced that it has obtained Breakthrough Therapy Designation (BTD) from...

Company Deals

Mabwell Bioscience Grants Qilu Pharma Exclusive Rights to Mailisheng in Greater China

Fineline Cube Jun 27, 2025

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) announced a licensing agreement with compatriot firm...

Company Drug

Fosun Pharma’s Serplulimab Approved for ES-SCLC in the UK and India

Fineline Cube Jun 26, 2025

Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196, SHA: 600196) announced that its subsidiary Shanghai...

Company Drug

Sanofi’s Riliprubart Granted Orphan Drug Status for Antibody-Mediated Rejection Treatment

Fineline Cube Jun 26, 2025

France-based major Sanofi (NASDAQ: SNY) has secured Orphan Drug Designation (ODD) from the US Food...

Company Drug

Bio-Thera Solutions Initiates Phase III Trial of BAT8006 for Platinum-Resistant Ovarian Cancer

Fineline Cube Jun 26, 2025

Guangzhou-based Bio-Thera Solutions (SHA: 688177) announced the successful first patient dosing in its Phase III...

Company

AstraZeneca Restructures to Form Gastrointestinal Oncology Business Unit

Fineline Cube Jun 26, 2025

UK major AstraZeneca (AZ, NASDAQ: AZN) this week reportedly unveiled a new organizational restructuring plan,...

Company Drug

EMA Panel Recommends Brukinsa Tablet Formulation for Approval

Fineline Cube Jun 26, 2025

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...

Company Drug

Sinocelltech Wins NMPA Clearance for TriAb SCTB39G in Solid Tumors

Fineline Cube Jun 26, 2025

China-based Sinocelltech Group Ltd (SHA: 688520) announced that it has received clearance from the National...

Company Drug

CARsgen’s Satri-cel NDA Accepted by China’s NMPA for Gastric Adenocarcinoma

Fineline Cube Jun 26, 2025

China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) announced that the National Medical Products Administration (NMPA)...

Company Drug

Lepu Biopharma Gains EMA Approval for MRG003 HNSCC Clinical Trial

Fineline Cube Jun 26, 2025

China-based Lepu Biopharma Co., Ltd (HKG: 2157) announced that it has received approval from the...

Company Deals

RemeGen Inks Global Licensing Pact With Vor Biopharma for Telitacicept

Fineline Cube Jun 26, 2025

China-based RemeGen Co., Ltd. (SHA: 688331, HKG: 9995) announced an exclusive licensing agreement with U.S.-based...

Company Drug

Angel Pharma Gains NMPA Approval for Soquelitinib in Atopic Dermatitis Trial

Fineline Cube Jun 26, 2025

China-based Angel Pharmaceuticals Ltd announced that it has received approval from the National Medical Products...

Company Drug

Biogen’s Phase I Results Highlight Salanersen’s Potential in Spinal Muscular Atrophy

Fineline Cube Jun 26, 2025

Biogen (NASDAQ: BIIB) announced this week topline results from the Phase I study of salanersen...

Company Deals Drug

Kymera and Sanofi Advance IRAK4 Program With Selection of KT-485 for Clinical Development

Fineline Cube Jun 26, 2025

US-based Kymera Therapeutics Inc. (NASDAQ: KYMR) announced updates to its IRAK4-targeted program collaboration with Sanofi....

Company Drug

LG Chem’s Cross-Linked Sodium Hyaluronate Gel Gains NMPA Approval for Midface Use

Fineline Cube Jun 26, 2025

South Korea’s LG Chem announced that its cross-linked sodium hyaluronate gel with lidocaine has received...

Company Deals

Porton Advanced Partners With EVA Pharma to Boost CAR-T Cell Therapy in MENA

Fineline Cube Jun 26, 2025

China-based Contract Development and Manufacturing Organization (CDMO) Porton Advanced Solutions Ltd. has entered into a...

Company Drug

Eli Lilly’s Amyvid Sees FDA-Approved Label Update for Alzheimer’s Diagnosis

Fineline Cube Jun 26, 2025

US-based Eli Lilly & Co. (NYSE: LLY) announced the US Food and Drug Administration (FDA)...

Company Deals

Gilead Signs Licensing Pact With Kymera Therapeutics for CDK2-Targeted MGD

Fineline Cube Jun 26, 2025

US major Gilead Sciences, Inc. (NASDAQ: GILD) this week entered into an exclusive option and...

Company Drug

SineuGene’s ALS Gene Therapy SNUG01 Granted FDA Orphan Drug Designation

Fineline Cube Jun 26, 2025

Beijing-based SineuGene Therapeutics, a developer of gene therapies for brain disorders, announced this week that...

Company Drug

Acotec Scientific Wins NMPA Approval for Armoni-HP Balloon Catheter

Fineline Cube Jun 26, 2025

China-based Acotec Scientific Holdings Ltd (HKG: 6669) announced that it has received marketing approval from...

Posts pagination

1 … 163 164 165 … 693

Recent updates

  • Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients
  • Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs
  • Shenyang Xingqi Pharmaceutical Reports Positive Phase 2 Results for SQ-22031 Eye Drops in Neurotrophic Keratitis, Advances to Pivotal Phase 3 Trial
  • Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST
  • Changchun High & New Technology’s Subsidiary GenSci Secures NMPA IND Acceptance for GenSci148, First-in-Class VEGF Multi-Blocker for Retinal Vascular Diseases
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients

Company Drug

Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs

Company Drug

Shenyang Xingqi Pharmaceutical Reports Positive Phase 2 Results for SQ-22031 Eye Drops in Neurotrophic Keratitis, Advances to Pivotal Phase 3 Trial

Company Deals

Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.